*Corresponding author; #co-first author; Yang Lab members shown in bold.

Research Articles

• Kim S#, Son E#, Park HR, Kim M, Yang H*. Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. J Clin Invest. 2025 Oct 15;135(20):e188839. doi: 10.1172/JCI188839. PMID: 40794455; PMCID: PMC12520673. https://www.jci.org/articles/view/188839

• Kim K, Armand J, Kim S, Yang H*. E2F activity determines mitosis versus whole-genome duplication in G2-arrested cells. Nat Commun. 2025;16:6677. https://www.nature.com/articles/s41467-025-62061-w

• Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang H*. Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. eLife. 2025;14:RP104545. https://elifesciences.org/articles/104545

• Park HR, Shiva A, Cummings P, Kim S, Kim S, Lee E, Leong A, Chowdhury S, Shawber C, Carvajal R, Thurston G, An JY, Lund AW, Yang H, Kim M*. Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma. Cancer Res. 2023 Jun 15;83(12):1968-1983. PMID: 37093870; PMCID: PMC10267677. (Cover article) https://aacrjournals.org/cancerres/article/83/12/1968/727168/Angiopoietin-2-Dependent-Spatial-Vascular

• Lee E#, O'Keefe S#, Leong A#, Park HR, Varadarajan J, Chowdhury S, Kim S, Shiva A, Friedman RA, Remotti H, Fojo T, Yang H, Thurston G, Kim M*. Angiopoietin-2 promotes hepatic metastatic growth by restricting T-cell infiltration to the liver in pancreatic neuroendocrine tumors. J Clin Invest. 2023 Oct 16;133(20):e167994. doi: 10.1172/JCI167994. PMID: 37843277. https://www.jci.org/articles/view/167994

• Zhang M#, Kim S#, Yang H*. Non-canonical pathway for Rb inactivation and external signaling sequentially coordinate cell-cycle entry without CDK4/6 activity. Nat Commun. 2023;14:7847. https://www.nature.com/articles/s41467-023-43716-y

• Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang H*. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Rep. 2023 Nov 28;42(11):113198. doi: 10.1016/j.celrep.2023.113198. PMID: 37865915. https://www.sciencedirect.com/science/article/pii/S221112472301210X?via%3Dihub

• Kim S, Carvajal R, Kim M, Yang H*. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Rep. 2023 Jun 27;42(6):112570. doi: 10.1016/j.celrep.2023.112570. PMID: 37252843. https://www.sciencedirect.com/science/article/pii/S2211124723005818?via%3Dihub

• Kim S, Leong A, Kim M*, Yang H*. CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. Sci Rep. 2022 Oct 7;12(1):16810. doi: 10.1038/s41598-022-20769-5. PMID: 36207346; PMCID: PMC9546874. https://www.nature.com/articles/s41598-022-20769-5

• Nguyen T, Shang E, Shu C, Kim S, Mela A, Humala N, Mahajan A, Yang H, Akman H, Quinzii C, Zhang G, Westhoff M, Karpel-Massler G, Bruce J, Canoll P, Siegelin M. Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nat Commun. 2021;12:5203. https://www.nature.com/articles/s41467-021-25501-x

• Resnick SJ, Iketani S, Hong SJ, Zask A, Liu H, Kim S, Melore S, Nair MS, Huang Y, Tay NES, Rovis T, Yang H, Stockwell BR, Ho DD, Chavez A. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. J Virol. 2021;95(7):e02374-20. https://journals.asm.org/doi/10.1128/jvi.02374-20

• Meir R, Hirschhorn T, Kim S, Fallon KJ, Churchill EM, Wu D, Yang H, Stockwell BR, Campos LM. Photon upconversion hydrogels for 3D optogenetics. Adv Funct Mater. 2021. https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adfm.202010907?af=R